Form D · Other
Altrartis Therapeutics Inc.
New York, NY · CIK 0002157050
Offering snapshot reported Oct 22, 2026 · SEC filing
- Reported sold
- $11M Offering amount: $11M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 12, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 22, 2026 | Initial | $10,999,977 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-602187
Source: Form D, filed Oct 22, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Florian Brand | Director, Executive, Promoter |
| Lars Christian Wilde | Director |
Issuer details
Industry: Other (See others in industry)
Address:
228 Park Ave S # 505778
New York, NY, 10003-1502
New York, NY, 10003-1502